Emergent BioSolutions Inc. (NYSE:EBS) Shares Purchased by Cwm LLC

Cwm LLC boosted its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 32,706.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,921 shares of the biopharmaceutical company’s stock after buying an additional 4,906 shares during the period. Cwm LLC’s holdings in Emergent BioSolutions were worth $34,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD raised its holdings in shares of Emergent BioSolutions by 22.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 4,409 shares during the period. Assenagon Asset Management S.A. raised its stake in Emergent BioSolutions by 0.6% during the first quarter. Assenagon Asset Management S.A. now owns 839,414 shares of the biopharmaceutical company’s stock worth $2,124,000 after purchasing an additional 5,042 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Emergent BioSolutions by 1.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 460,289 shares of the biopharmaceutical company’s stock valued at $1,105,000 after purchasing an additional 6,724 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of Emergent BioSolutions by 52.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 19,867 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 6,823 shares during the period. Finally, Avidian Wealth Solutions LLC acquired a new stake in shares of Emergent BioSolutions during the 1st quarter worth approximately $33,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Emergent BioSolutions Stock Up 8.9 %

Shares of NYSE:EBS opened at $10.50 on Thursday. The company has a market capitalization of $550.22 million, a price-to-earnings ratio of -0.95 and a beta of 1.62. Emergent BioSolutions Inc. has a 12-month low of $1.42 and a 12-month high of $15.10. The business has a 50-day moving average price of $9.17 and a 200 day moving average price of $5.31. The company has a current ratio of 1.08, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67.

Emergent BioSolutions (NYSE:EBS) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.35). The company had revenue of $254.70 million for the quarter, compared to analyst estimates of $199.47 million. Emergent BioSolutions had a negative net margin of 47.68% and a negative return on equity of 18.53%. During the same quarter in the prior year, the business earned ($1.06) earnings per share. Sell-side analysts expect that Emergent BioSolutions Inc. will post -1.98 EPS for the current year.

Insiders Place Their Bets

In related news, Director Kathryn C. Zoon sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $6.11, for a total transaction of $61,100.00. Following the completion of the transaction, the director now directly owns 54,482 shares in the company, valued at approximately $332,885.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is owned by insiders.

Analysts Set New Price Targets

Separately, Benchmark reiterated a “buy” rating and issued a $8.00 price objective on shares of Emergent BioSolutions in a report on Friday, August 16th.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.